General Information of the Drug (ID: M6APDG03347)
Name
Curcumin
Synonyms
curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
    Click to Show/Hide
Status
Phase 3
Structure
Formula
C21H20O6
InChI
1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
InChIKey
VFLDPWHFBUODDF-FCXRPNKRSA-N
PubChem CID
969516
TTD Drug ID
D07SDQ
VARIDT Drug ID
DR00559
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
Response Summary DNA [cytosine-5]-methyltransferase 3B (DNMT3B) is a therapeutic target for Curcumin. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Curcumin through regulating the expression of DNA [cytosine-5]-methyltransferase 3B (DNMT3B). [1], [2]
Matrix metalloproteinase-13 (MMP-13)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Curcumin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [4], [5]
Matrix metalloproteinase-9 (MMP-9)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Curcumin. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [6], [7]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [7], [8]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Curcumin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Curcumin through regulating the expression of P-glycoprotein 1 (ABCB1). [9], [10]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of P-glycoprotein 1 (ABCB1). [10], [11]
Prostaglandin G/H synthase 2 (COX-2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). [5], [12]
References
Ref 1 m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency. Clin Transl Med. 2022 Mar;12(3):e765. doi: 10.1002/ctm2.765.
Ref 2 DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18.
Ref 3 FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020 Apr 1;389(1):111894. doi: 10.1016/j.yexcr.2020.111894. Epub 2020 Feb 6.
Ref 4 Gelatinase inhibitors: a patent review (2011-2017). Expert Opin Ther Pat. 2018 Jan;28(1):31-46. doi: 10.1080/13543776.2018.1397132. Epub 2017 Nov 12.
Ref 5 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 6 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 7 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789. doi: 10.1371/journal.pone.0099789. eCollection 2014.
Ref 8 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 9 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. doi: 10.1016/j.canlet.2015.10.010. Epub 2015 Oct 20.
Ref 11 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 12 Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210. doi: 10.1016/j.clinthera.2014.07.007. Epub 2014 Aug 2.